ERBB2 and breast carcinoma: In 2020, we reported HER2DX, the first multivariable prognostic score in early-stage HER2-positive breast cancer that integrated tumour and nodal staging, TILs, intrinsic molecular subtype, and the expression of 13 individual genes.